Patents Assigned to Shionogi & Co., Ltd.
  • Publication number: 20190211114
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 11, 2019
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
  • Patent number: 10335401
    Abstract: The present invention relates to a compound represented by Formula (I): wherein X is, for example, C(?O); Z is, for example, C(?O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, R6 or B; R2 is, for example, hydrogen; R3 is, for example, substituted or unsubstituted alkyl; R4a is, for example, hydrogen; R4b is, for example, hydrogen; R5 is, for example, halogen; R6 is, for example, halogen; R7a is, for example, hydrogen; R7b is, for example, hydrogen; R8 is, for example, hydrogen; R9 is, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 2, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yuji Nishiura, Kana Kurahashi, Naoki Ohyabu, Yoshikazu Sasaki
  • Patent number: 10329285
    Abstract: Crystals of a quinazoline derivative are provided. The present invention relates to an acid addition salt of a compound represented by Formula (I): a pharmaceutical composition containing it, and the like.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 25, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yukio Tada, Yuusuke Tamura, Shuji Yonezawa, Kenichi Ishibashi
  • Publication number: 20190183866
    Abstract: Provided is a compound which is useful as an AMPK activator, represented by formula: wherein the symbols are defined in the specification.
    Type: Application
    Filed: May 19, 2017
    Publication date: June 20, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yuusuke TAMURA, Toshihiro WADA
  • Publication number: 20190169206
    Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 6, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
  • Publication number: 20190161501
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: May 30, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hiroyuki TOBINAGA, Koji MASUDA, Satoshi KASUYA, Masanao INAGAKI, Mitsuhiro YONEHARA, Manami MASUDA
  • Patent number: 10294241
    Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 21, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Makoto Kawai
  • Publication number: 20190144396
    Abstract: The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L1- is —O—(CR6R7)m- or the like; -L2- is —O—(CR6R7)n- or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Naoki OHYABU, Kana KURAHASHI, Yuji NISHIURA, Manabu KATOU, Keisuke MIYAZAKI, Yoshikazu SASAKI, Toshihiro WADA, Masafumi IWATSU
  • Publication number: 20190135847
    Abstract: The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.
    Type: Application
    Filed: December 28, 2018
    Publication date: May 9, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Keisuke MIYAZAKI, Kenji TAKAYA, Takafumi OHARA, Hideki SUGIMOTO, Manabu FUJITANI, Yuki OGATA, Naoyuki SUZUKI
  • Publication number: 20190135834
    Abstract: Provided is a compound which is useful as an AMPK activator. The compound is represented by formula: wherein the symbols are defined in the specification.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 9, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yuusuke TAMURA, Yoshikazu SASAKI
  • Publication number: 20190119677
    Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.
    Type: Application
    Filed: April 13, 2017
    Publication date: April 25, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yukihiro AKAO, Yukio KITADE, Mitsuaki SEKIGUCHI, Yasunori MITSUOKA, Akira KUGIMIYA, Yasuo SASAKI
  • Publication number: 20190112315
    Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
  • Patent number: 10246478
    Abstract: The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: April 2, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Keisuke Miyazaki, Kenji Takaya, Takafumi Ohara, Hideki Sugimoto, Manabu Fujitani, Yuki Ogata, Naoyuki Suzuki
  • Patent number: 10239955
    Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 26, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
  • Patent number: 10233156
    Abstract: The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; —L1— is —O—(CR6R7)m— or the like; —L2— is —O—(CR6R7)n— or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 19, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Naoki Ohyabu, Kana Kurahashi, Yuji Nishiura, Manabu Katou, Keisuke Miyazaki, Yoshikazu Sasaki, Toshihiro Wada, Masafumi Iwatsu
  • Publication number: 20190071508
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicants: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Tetsuya YOSHIDA, Yujiro KIDANI, Mitsunobu MATSUMOTO, Takayuki KANAZAWA, Satomi SHINONOME, Kanji HOJO, Naganari OHKURA, Shimon SAKAGUCHI, Atsushi TANAKA, Hisashi WADA, Atsunari KAWASHIMA, Norio NONOMURA
  • Publication number: 20190062282
    Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 28, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Akira YUKIMASA, Kenichiroh NAKAMURA, Tohru HORIGUCHI, Kazuya KANO, Takatsugu INOUE
  • Publication number: 20190060293
    Abstract: Provided is a compound which is useful as an AMPK activator. The compound is represented by formula: wherein the symbols are defined in the specification.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 28, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yuusuke TAMURA, Hiroki OZASA
  • Patent number: 10202379
    Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 12, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Chika Takahashi, Hidenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa
  • Patent number: 10202404
    Abstract: The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: February 12, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tomokazu Yoshinaga, Kouhei Nodu